Growth monitoring as an early detection tool: a systematic review

Pauline Scherdel1, Leo Dunkel2, Paula van Dommelen3

  • 1Early Determinants of the Child's Health and Development Team (ORCHAD), INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Université Paris Descartes, Paris, France; Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Université Paris Descartes, Paris, France; Paris-Sud University, Paris, France.

Insights

Current growth monitoring practices often use suboptimal methods, delaying diagnoses. This review highlights the need for standardized growth monitoring with validated rules and appropriate charts for early detection of childhood disorders.

Area of Science:

  • Pediatric endocrinology
  • Clinical genetics
  • Public health

Background:

  • Growth monitoring is crucial for early detection of childhood disorders.
  • Existing methods are often suboptimal, leading to delayed diagnoses and inappropriate referrals.

Purpose of the Study:

  • To identify target conditions for growth monitoring.
  • To evaluate methods for defining abnormal growth.
  • To assess the performance of growth charts in early disease detection.

Main Methods:

  • Systematic review of studies on growth monitoring algorithms and growth chart performance.
  • Included 69 studies from 1556 identified citations.
  • Focused on conditions like Turner syndrome, coeliac disease, cystic fibrosis, and growth hormone deficiency.

Main Results:

  • Six target conditions were frequently studied.
  • Seven algorithms for abnormal growth lack robust validation, with Grote and Saari rules showing promise.
  • WHO growth charts demonstrated poorer performance in early detection compared to others.

Conclusions:

  • A significant gap exists between growth monitoring implementation and evidence-based practice.
  • Further research is needed to standardize growth monitoring.
  • Consensus on priority conditions and validated clinical decision rules, including appropriate growth charts, is essential.